PTHLH and breast carcinoma: Therefore, two clinical trials (NCT00051779 and NCT00060138) were initiated in 2003 to evaluate the safety, tolerability, and possible effectiveness of the humanized monoclonal antibody against PTHrP in patients with breast cancer metastatic to bone, compared to zoledronic acid.